THE J DAVID GLADSTONE INSTITUTES

Discovered the mechanism of CD4 T-cell death in HIV infection, conducted the first pivotal multinational trial showing antiretroviral drugs can prevent HIV in high-risk individuals, and maintains an ongoing research program in virology.

Discovered the mechanism of CD4 T-cell death in HIV infection, conducted the first pivotal multinational trial showing antiretroviral drugs can prevent HIV in high-risk individuals, and holds 211 patents related to virology and infectious disease research.

Discovered the mechanism of CD4 T-cell death in HIV infection, conducted the first pivotal multinational trial showing antiretroviral drugs can prevent HIV infection in high-risk individuals, and holds 211 patents related to virology and infectious disease.

Conducts high-impact translational research, including discoveries related to HIV pathogenesis, Alzheimer’s disease mechanisms (APOE variants), and clinical trials for HIV prevention; published over 200 papers in 2024 and holds 211 patents.

Combines artificial intelligence models with advanced laboratory technologies to analyze and interpret the human genome, supporting data-driven biomedical discovery.

Combines artificial intelligence models with advanced laboratory tools to analyze and interpret the human genome, advancing data science applications in biomedicine.

Conducts research across five interconnected institutes focusing on cardiovascular disease, data science and biotechnology, genomic immunology, neurological disease, and virology. This includes foundational discoveries, clinical trials, and the use of AI models to analyze the human genome, resulting in numerous scientific publications and patents.

Operates five interconnected research institutes focused on cardiovascular disease, data science and biotechnology, genomic immunology, neurological disease, and virology. This includes conducting basic and translational research, such as discovering mechanisms of HIV infection, identifying genetic factors in Alzheimer's disease, and analyzing the human genome using AI models, publishing over 200 papers annually.

Operates five interconnected research institutes focused on cardiovascular disease, data science and biotechnology, genomic immunology, neurological disease, and virology. This includes conducting basic and translational research, such as discovering mechanisms of HIV infection, identifying genetic factors in Alzheimer's disease, and analyzing the human genome using AI models, resulting in over 200 scientific publications in 2024 and 211 patents.

Determined the structure and function of apolipoprotein E, identified its three human variants (APOE2, APOE3, APOE4), and discovered that APOE4 causes amyloid plaque accumulation in Alzheimer’s disease while certain variants prevent plaque formation, revealing potential therapeutic pathways.

Conducted $28 million in commercially sponsored research over the past five years, indicating active collaboration with industry partners on applied biomedical research.

Determined the structure and function of apolipoprotein E, identified its three human variants (APOE2, APOE3, APOE4), and discovered that APOE4 causes amyloid plaque accumulation in Alzheimer’s disease, while certain variants prevent plaque formation, revealing therapeutic pathways.

Operates five interconnected research institutes focused on cardiovascular disease, data science and biotechnology, genomic immunology, neurological disease, and virology, integrating interdisciplinary collaboration through established research centers and Bay Area partnerships.

Operates five interconnected research institutes focused on cardiovascular disease, data science and biotechnology, genomic immunology, neurological disease, and virology, integrating interdisciplinary collaboration through established research centers and partnerships across the Bay Area.

Combines artificial intelligence models with advanced laboratory tools to analyze and interpret the human genome, advancing data-driven approaches in biomedical research.

Determined the structure and function of apolipoprotein E, identified its three human variants (APOE2, APOE3, APOE4), discovered that APOE4 causes amyloid plaque accumulation in Alzheimer’s, and demonstrated that certain variants can prevent plaque formation, revealing therapeutic pathways.

Published over 200 scientific papers in 2024 and conducted $28 million in commercially sponsored research over the past five years, demonstrating sustained research output and industry collaboration.

Published over 200 scientific papers in 2024 and holds 211 patents, reflecting a robust output of peer-reviewed research and intellectual property.

Hosts an annual award ceremony that includes a scientific lecture and presents an unrestricted $150,000 prize to researchers who have made significant advancements in cellular reprogramming technology for regenerative medicine.

Hosts an annual award ceremony featuring a scientific lecture and awards an unrestricted $150,000 prize to researchers who have advanced cellular reprogramming technology for regenerative medicine.

Hosts an annual award ceremony featuring a scientific lecture and awards an unrestricted $150,000 prize to researchers who have advanced cellular reprogramming technology for regenerative medicine through translational research.

Hosts an annual award ceremony featuring a scientific lecture and awards an unrestricted $150,000 prize to researchers who have advanced cellular reprogramming technology for regenerative medicine.

Hosts an annual award ceremony featuring a scientific lecture and awards an unrestricted $150,000 prize to researchers who have advanced cellular reprogramming technology for regenerative medicine through translational research.

Published over 200 scientific papers in 2024 and conducted $28 million in commercially sponsored research over the past five years.

Conducted $28 million in commercially sponsored research over five years and supports the founding of start-ups; Gladstone-backed companies have raised $2.5 billion and include Tenaya Therapeutics, spun off in 2016.

Constructed a 200,000-square-foot biomedical research building and expanded its research footprint by adding 105,000 square feet of new laboratory space in San Francisco's Mission Bay neighborhood.

Completed construction of a 200,000-square-foot biomedical research building and added 105,000 square feet of new laboratory space in San Francisco's Mission Bay neighborhood to support growing research operations.

Completed construction of a 200,000-square-foot biomedical research building and expanded laboratory space by 105,000 square feet in San Francisco's Mission Bay neighborhood to support growing research operations.

Completed construction of a 200,000-square-foot biomedical research building and expanded laboratory space by 105,000 square feet in San Francisco's Mission Bay neighborhood to support growing research operations.

Completed construction of a 200,000-square-foot biomedical research building and expanded laboratory space by 105,000 square feet in San Francisco's Mission Bay neighborhood to support growing research operations.

Actively facilitates collaboration among experts from diverse scientific and administrative backgrounds to address major scientific challenges, accelerate discovery, and develop enabling technologies.

Facilitates collaboration among experts from diverse backgrounds to address major scientific challenges and leverages complementary scientific and administrative expertise to accelerate research progress.

Runs BioFulcrum, an entrepreneurial program that advances disease-related research toward clinical trials via collaborations with scientists, nonprofits, and industry partners; supported the founding of 15 start-ups since 2015, including Tenaya Therapeutics, which was spun off in 2016 based on Gladstone research.

Offers state-of-the-art core research facilities that are accessible to scientists within Gladstone, UC San Francisco, and other Bay Area research institutions, fostering interdisciplinary collaboration.

Operates state-of-the-art core research facilities accessible to scientists at Gladstone, UC San Francisco, and other Bay Area research institutions, supporting advanced biomedical experimentation and analysis.

Operates state-of-the-art core research facilities accessible to scientists at Gladstone, UC San Francisco, and other Bay Area research institutions, supporting advanced experimentation and technology development.

Operates state-of-the-art core research facilities accessible to scientists at Gladstone, UC San Francisco, and other Bay Area research institutions, supporting advanced experimentation and technology development.

Offers state-of-the-art core research facilities accessible to scientists at Gladstone, UC San Francisco, and other Bay Area institutions, supporting advanced experimentation and technology development.

Hosts an annual award ceremony that includes a scientific lecture and awards an unrestricted $150,000 prize to researchers who have significantly advanced cellular reprogramming technology for regenerative medicine through translational research.

Provides financial and advisory support to advance biological research, operates state-of-the-art core research facilities accessible to scientists, and facilitates interdisciplinary collaboration among experts. This includes developing new laboratory spaces and fostering an environment for scientific advancement.

Recognizes researchers who have made significant advancements in cellular reprogramming technology for regenerative medicine through an annual award ceremony, which includes a scientific lecture and a monetary prize. The organization also trains graduate students and postdoctoral researchers to become leaders in biomedical science.

Gladstone-backed start-ups have raised $2.5 billion from public and private financing, demonstrating strong commercial validation and financial capacity to translate research into real-world applications.

Has supported the founding of 15 start-ups since 2015, including Tenaya Therapeutics (founded in 2016), with Gladstone-backed companies raising $2.5 billion in public and private financing.

Has supported the founding of 15 start-ups by its scientists since 2015, including Tenaya Therapeutics (founded in 2016), with Gladstone-backed companies raising $2.5 billion in public and private financing.

Establishes and supports entrepreneurial programs like BioFulcrum to advance disease-related research toward clinical trials, leading to the founding of 15 start-ups since 2015, which have collectively raised $2.5 billion. The organization also holds 211 patents and conducts commercially sponsored research.

Provides financial and advisory support to its institutes, offers state-of-the-art core research facilities to scientists at Gladstone, UC San Francisco, and other Bay Area institutions, and facilitates collaboration among experts. This includes establishing an entrepreneurial program, BioFulcrum, to advance disease-related research toward clinical trials and supporting the founding of 15 start-ups by its scientists since 2015, which have raised $2.5 billion.

Operates BioFulcrum, an entrepreneurial program that advances disease-related research toward clinical trials through collaboration with scientists, nonprofits, and industry partners.

Trains graduate students and postdoctoral researchers to become leaders in biomedical science.

Provides training to graduate students and postdoctoral researchers, preparing them to become leaders in the field of biomedical science.

Trains graduate students and postdoctoral researchers to become leaders in biomedical science, contributing to workforce development in the field.

Trains graduate students and postdoctoral researchers to become leaders in biomedical science, contributing to long-term capacity building in the research ecosystem.

Trains graduate students and postdoctoral researchers to become leaders in biomedical science, contributing to long-term capacity in the research ecosystem.

Trains graduate students and postdoctoral researchers to become leaders in biomedical science through immersive research experiences and mentorship.

Runs BioFulcrum, an entrepreneurial program that advances disease-related research toward clinical trials through collaboration with scientists, nonprofits, and industry partners, and has conducted $28 million in commercially sponsored research over five years.

Advances disease-related research toward clinical trials through entrepreneurial programs like BioFulcrum, which collaborates with scientists, nonprofits, and industry partners. This also involves spinning off biotech companies based on Gladstone research and supporting the founding of start-ups by its scientists.